On March 16, 2026, WW International, Inc. (Nasdaq: WW) announced its financial results for the fourth quarter and full year ended December 31, 2025. The company reported total revenue of $163 million for Q4, which represents a 32% increase in Clinical Subscription Revenue year-over-year. The total end of period subscribers reached 2.8 million, with clinical subscribers growing by 42% year-over-year. Despite a net loss of $6 million for the quarter, the company’s Adjusted EBITDA was $18 million, reflecting an 11.1% margin. The results exceeded previously provided guidance for both revenue and Adjusted EBITDA, indicating a positive trajectory for the company as it navigates the evolving weight management landscape influenced by GLP-1 medications. CEO Tara Comonte emphasized the company's commitment to integrating clinical capabilities with behavioral support, positioning Weight Watchers as a leader in the weight health market. The company also provided guidance for Q1 2026, estimating approximately 2.65 million total end of period subscribers and full year revenue guidance of $620 million to $635 million. This strong performance and outlook suggest a positive impact on the stock price, as the company continues to adapt to market changes and consumer needs.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.